Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simulation of hepatitis C based on a mandatory reporting system.

Markus Sagmeister1, Eberhard L Renner, Beat Mullhaupt

  • 1Division of Gastroenterology and Hepatology, University Hospital, Zürich, Switzerland.

European Journal of Gastroenterology & Hepatology
|January 10, 2002
PubMed
Summary

Hepatitis C virus (HCV) infection prevalence in Switzerland is higher than previously estimated. Despite decreasing new infections, HCV-related disease burden and costs will significantly increase until 2020.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peribiliary cysts on MRI: review of imaging features and associated clinical features.

Abdominal radiology (New York)·2026
Same author

Surgical management of cystic echinococcosis-A 20-year case series and outcome analysis.

PLoS neglected tropical diseases·2026
Same author

Efficacy and safety of bulevirtide in patients with chronic hepatitis D treated under early access in Switzerland: a retrospective analysis.

Swiss medical weekly·2026
Same author

Survival and quality of life after liver transplantation in patients with or without pre-transplant alcohol abstinence: a retrospective cohort study.

Swiss medical weekly·2025
Same author

Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network.

Swiss medical weekly·2025
Same author

Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project.

The Lancet. Infectious diseases·2025

Area of Science:

  • Hepatology
  • Epidemiology
  • Public Health

Background:

  • Hepatitis C is a significant cause of liver disease in Europe.
  • Accurate assessment of hepatitis C burden is crucial for public health planning.

Purpose of the Study:

  • To assess the current and future disease burden of hepatitis C in Switzerland.
  • To estimate hepatitis C prevalence, morbidity, mortality, and associated costs.

Main Methods:

  • Utilized a unique epidemiological database from mandatory reporting of hepatitis C virus (HCV) test results and physician-collected clinical data in Switzerland.
  • Applied a validated computer model simulating the natural history of HCV infection.
  • Estimated age distribution of acute and chronic HCV infections, prevalence, future morbidity/mortality (cirrhosis, hepatocellular carcinoma), and costs.

Related Experiment Videos

Main Results:

  • Estimated anti-HCV prevalence in Switzerland at 1.25-1.75%, exceeding prior reports.
  • Predicted a 70-90% increase in HCV-related morbidity and mortality, peaking between 2015-2020, driven by prevalent cases from 1998.
  • Antiviral treatment demonstrated a modest 5% reduction in disease burden.
  • Projected annual direct costs to more than double, reaching nearly US$33 million by 2020.

Conclusions:

  • HCV-related cirrhosis incidence is expected to decline post-2005-2010.
  • Disease burden and complication costs associated with hepatitis C are projected to rise until 2015-2020.